A5063602878- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood groups and transfusion
- Retinoids in leukemia and cellular processes
- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Platelet Disorders and Treatments
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- Liver Disease and Transplantation
- Childhood Cancer Survivors' Quality of Life
- Pneumocystis jirovecii pneumonia detection and treatment
- Adenosine and Purinergic Signaling
- Hematological disorders and diagnostics
- Multiple Myeloma Research and Treatments
- Immune cells in cancer
- Hemoglobinopathies and Related Disorders
- Advanced biosensing and bioanalysis techniques
- COVID-19 Clinical Research Studies
- Epigenetics and DNA Methylation
- Polyomavirus and related diseases
- COVID-19 and healthcare impacts
- Immune Cell Function and Interaction
Peking University People's Hospital
2021-2025
Peking University
2021-2025
National Clinical Research
2023-2024
King University
2023
Research on the comprehensive integration of clinical and genomic characteristics in patients with core binding factor acute myeloid leukemia (CBF-AML) is limited. Clinical data from consecutive CBF-AML were reviewed. A Cox regression model was used to identify variables associated event-free survival (EFS), relapse-free (RFS) overall (OS). total 346 (211 RUNX1::RUNX1T1 135 CBFB::MYH11) included this study. In cohort, multivariate analyses revealed that KDM6A mutations significantly poor RFS...
Abstract The Phase 3 single‐arm COMMODORE study ( ClinicalTrials.gov , NCT04654468) evaluated efficacy and safety of crovalimab (novel C5 inhibitor) in complement inhibitor‐naive patients with paroxysmal nocturnal hemoglobinuria (PNH). enrolled from five China centers. Eligible PNH were ≥12 years old, had lactate dehydrogenase (LDH) ≥2 × upper limit normal (ULN), ≥4 transfusions packed red blood cells within the prior 12 months. Patients received loading doses (one intravenous, four...
Summary As the COVID‐19 variant Omicron surge in Beijing, China, a better understanding of risk factors for adverse outcomes may improve clinical management patients with haematological malignancies (HM) diagnosed COVID‐19. The study sample includes 412 cases, mainly represented by acute leukaemia, chronic myeloid leukaemia (CML), plasma cell disorders and lymphoma lymphocytic leukaemia. pneumonia was observed 10.4% (43/412) patients, severe/critical illness 5.3% (22/412). Among 86 cases...
The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS).In this trial, 191 adult patients with intermediate/high MDS (IPSS score ≥ 0.5) randomly received using a regimen (20 mg/m2 /day 5 consecutive days; n = 94) an extended lower daily dose (12 8 97) every 4 weeks, total of cycles.The median follow-up was 14 months (range 2-36). primary end point overall response rate in intent-to-treat analysis 41.5% and 38.1% dosing arms,...
Summary Despite the high cure probability for acute promyelocytic leukaemia (APL), a minority of patients will relapse and risk factors are unclear. We retrospectively analysed 212 who were diagnosed with non‐high‐risk APL received all‐ trans retinoic acid (ATRA) plus arsenic as front‐line therapy at Peking University Institute Hematology from February 2014 to December 2018. A total 176 (83%) oral (realgar‐indigo naturalis formula) ATRA, 36 (17%) trioxide ATRA 203 evaluable relapse. After...
Summary There is an urgent need for oral, efficient and safe regimen high‐risk APL under the pandemic of COVID‐19. We retrospectively analysed 60 patients. For induction therapy (IT), in addition to all‐trans retinoic acid (ATRA) oral arsenic (RIF), 22 patients received etoposide (VP16) as cytotoxic chemotherapy (CC), 38 intravenous CC historical control group. The median dose VP16 was 1000 mg [interquartile rage (IQR), 650–1250]. One patient died during IT group, 59 evaluable (100%)...
<title>Abstract</title> Venetoclax combined with azacitidine (VA) is a new standard of care for newly diagnosed patients acute myeloid leukemia (AML) who are unfit intensive chemotherapy. We retrospectively analyzed were favorable-risk AML and received VA-based induction regimen between October 2020 December 2023 in our center. Among 70 patients, 14 had RUNX1::RUNX1T1, 11 CBFb::MYH11, CEBPA bzip mutations 31 NPM1 mutations. The median age was 60 years (IQR 49–67) the follow-up 18.0 months...
Abstract The authors have requested that this preprint be removed from Research Square.
7052 Background: Hypomethylating agents (HMAs) are the preferred treatment for untreated patients (pts) with higher-risk MDS, but survival of pts after HMAs is poor. It has been demonstrated that PD-1/PD-L1 expression was upregulated by in MDS pts, providing a strong rationale combining PD-1 antibody treatment. Therefore, this single-arm, open-label, clinical trial performed to evaluate safety and efficacy Sintilimab plus decitabine (ChiCTR2100044393). Methods: Adult IPSS-R were enrolled....